StockWatch
·
Pharmaceuticals
Quarterly Result4 Nov 2026, 01:44 pm

Marksans Pharma Q2FY27 Revenue Crosses ₹900 Cr, EBITDA Up 48%

AI Summary

Marksans Pharma reported its Q2FY27 unaudited financial results, marking a landmark quarter with revenue reaching ₹940 crore, a 30.5% year-on-year increase. EBITDA surged by 48.3% to a record ₹214 crore, with margins expanding to 22.8%. For the first half of FY27 (H1FY27), revenue grew 32.9% to ₹1,781 crore, EBITDA rose 74.7% to ₹427 crore, and Profit After Tax (PAT) nearly doubled to ₹303 crore. The company saw broad-based growth across regions, with the US & North America and UK & Europe markets achieving their highest-ever quarterly revenues. Operating cash flow for H1FY27 was ₹322 crore, a significant increase from the previous year. The company highlighted a strong net-cash position and confidence in its growth trajectory, focusing on profitable organic growth and strategic acquisitions.

Key Highlights

  • Q2FY27 revenue reached ₹940 crore, up 30.5% YoY.
  • Q2FY27 EBITDA increased 48.3% to a record ₹214 crore.
  • H1FY27 PAT nearly doubled to ₹303 crore.
  • US & Europe markets achieved record quarterly revenues.
  • Operating cash flow for H1FY27 was ₹322 crore, 4.3x H1FY26.